Treatment of Burkitt leukemia/lymphoma in adults - UpToDate
WEBMar 11, 2024 · Burkitt lymphoma (BL) is a highly aggressive B cell neoplasm characterized by the translocation and deregulation of the MYC gene on chromosome 8. Three distinct clinical forms of BL are recognized: endemic, sporadic, and immunodeficiency-associated.
Burkitt lymphoma | HemOnc.org - A Hematology Oncology Wiki
WEBLacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004 Apr;45(4):761-7.
Modified magrath regimens for adults with Burkitt and Burkitt …
WEBHigh-risk patients received four alternating cycles of regimens A and B (A-B-A-B). Regimen B consisted of ifosfamide, cytarabine, etoposide and intrathecal methotrexate (IVAC). The modified treatment regimen was associated with no grade 3/4 neuropathy and only one episode of grade 3/4 mucositis.
Approach to the Diagnosis and Treatment of Adult Burkitt's …
WEBJun 14, 2018 · Abstract. Burkitt's lymphoma is a rarely encountered, aggressive B-cell lymphoma that is highly curable in children and young adults. In middle-aged and older adults, however, administering curative therapy may be challenging because standard Burkitt's lymphoma platforms are associated with high treatment-related toxicity in …
Burkitt Lymphoma: An International Prognostic Index : Oncology …
WEBLacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004;45:761–7 Cited Here |
Is Dose-adjusted EPOCH-R Enough in Burkitt Lymphoma?
WEBOct 6, 2020 · The modified Magrath regimen is a spin-off of the original, with some key dose modifications to improve tolerability in adults. Even with these modifications, the regimen is a significant challenge to administer to patients older than 40 years, as is hyper-CVAD, which is really a childhood acute lymphoblastic leukemia regimen.
How I treat Burkitt lymphoma in adults | Blood - American …
WEBNov 6, 2014 · In patients younger than 60 years of age, including those with well-controlled HIV, and those up to 70 years of age with good baseline functional status, previously normal marrow reserve and immune status without significant underlying cardiac or renal dysfunction, we favor the modified-Magrath regimen. 58 …
WEB3. Lacasce A, Howard O, Li S, et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45: 761–767. 4. Dunleavy K, Wayne A, Little R, et al. The addition of rituximab to dose-adjusted EPOCH with HAART suspension is highly
IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin …
WEBNov 5, 2020 · Part B of the modified Magrath regimen (ifosfamide, etoposide, and cytarabine; IVAC) with or without rituximab (R) is utilized as a standalone regimen in the management of relapsed/refractory Burkitt lymphoma and …
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt ...
WEBOct 31, 2023 · A further modified Magrath regimen (dose-modified CODOX-M/IVAC), which reduced methotrexate and cytarabine doses from the original CODOX-M/IVAC protocol, was developed by Mead and colleagues 4 because of the low treatment completion rates seen in earlier reiterations of the protocol.